PharmacoEconomics

, Volume 28, Supplement 1, pp 35–47 | Cite as

The Impact of Disease Stage on Direct Medical Costs of HIV Management

A Review of the International Literature
  • Adrian Levy
  • Karissa Johnston
  • Lieven Annemans
  • Andrea Tramarin
  • Julio Montaner
Review Article

Abstract

The global prevalence of HIV infection continues to grow, as a result of increasing incidence in some countries and improved survival where highly active antiretroviral therapy (HAART) is available. Growing healthcare expenditure and shifts in the types of medical resources used have created a greater need for accurate information on the costs of treatment. The objectives of this review were to compare published estimates of direct medical costs for treating HIV and to determine the impact of disease stage on such costs, based on CD4 cell count and plasma viral load.

A literature review was conducted to identify studies meeting prespecified criteria for information content, including an original estimate of the direct medical costs of treating an HIV-infected individual, stratified based on markers of disease progression. Three unpublished cost-of-care studies were also included, which were applied in the economic analyses published in this supplement. A two-step procedure was used to convert costs into a common price year (2004) using country-specific health expenditure inflators and, to account for differences in currency, using health-specific purchasing power parities to express all cost estimates in US dollars.

In all nine studies meeting the eligibility criteria, infected individuals were followed longitudinally and a ‘bottom-up’ approach was used to estimate costs. The same patterns were observed in all studies: the lowest CD4 categories had the highest cost; there was a sharp decrease in costs as CD4 cell counts rose towards 100 cells/mm3; and there was a more gradual decline in costs as CD4 cell counts rose above 100 cells/mm3. In the single study reporting cost according to viral load, it was shown that higher plasma viral load level (>100 000 HIV-RNA copies/mL) was associated with higher costs of care. The results demonstrate that the cost of treating HIV disease increases with disease progression, particularly at CD4 cell counts below 100 cells/mm3. The suggestion that costs increase as the plasma viral load rises needs independent verification. This review of the literature further suggests that publicly available information on the cost of HAART by disease stage is inadequate. To address the information gap, multiple stakeholders (governments, pharmaceutical industry, private insurers and non-governmental organizations) have begun to establish and support an independent, high quality and standardized multicountry data collection for evaluating the cost of HIV management. An accurate, representative and relevant cost-estimate data resource would provide a valuable asset to healthcare planners that may lead to improved policy and decision-making in managing the HIV epidemic.

Notes

Acknowledgements

The authors gratefully acknowledge Brian Harrigan, Patrick Hoggard and Erik Smets. This project was financially supported by Johnson & Johnson Pharmaceutical Services with an unrestricted research grant to Oxford Outcomes, a consultancy specializing in contract research for a wide range of clients in the life sciences industry, including both public sector organizations as well as pharmaceutical and other private companies. AL is a shareholder in Oxford Outcomes Ltd. KJ is an employee of Oxford Outcomes Ltd. LA has received consultancy fees from Johnson & Johnson in the field of HIV/AIDS. JM has received grants from, served as an ad-hoc advisor to, or spoke at various events sponsored by Abbott, Argos Therapeutics, Bioject Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman-La Roche, Janssen-Ortho, Merck Frosst, Panacos, Pfizer, Serono Inc., TheraTechnologies, Tibotec (J&J) and Trimeris. AT declares no conflict of interest.

References

  1. 1.
    Fauci AS. The AIDS epidemic — considerations for the 21st century. N Engl J Med 1999; 341: 1046–50PubMedCrossRefGoogle Scholar
  2. 2.
    Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21: 685–92PubMedCrossRefGoogle Scholar
  3. 3.
    Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Euro SIDA Study Group. Lancet 1998; 352: 1725–30PubMedCrossRefGoogle Scholar
  4. 4.
    Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60PubMedCrossRefGoogle Scholar
  5. 5.
    Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867–73PubMedCrossRefGoogle Scholar
  6. 6.
    Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11–19PubMedCrossRefGoogle Scholar
  7. 7.
    Hogan DR, Salomon JA. Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings. Bull WHO 2005; 83: 135–43PubMedGoogle Scholar
  8. 8.
    European AIDS Clinical Society. European Treatment Guidelines. 2005 [online]. Available at: (http://www.europeanaidsclinicalsociety.org/Guidelines/index.htm) [Accessed 2010 Nov 28]Google Scholar
  9. 9.
    Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 Recommendations of the International AIDS Society — USA panel. JAMA 2006; 296: 827–43PubMedCrossRefGoogle Scholar
  10. 10.
    Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV infected adults with antiretroviral therapy (2006). HIV Med 2006; 7: 487–503PubMedCrossRefGoogle Scholar
  11. 11.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral agents in HIV-1-infected individuals. Department of Health and Human Services; 2009: 1–161 [online]. Available at: (http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf) [Accessed 2010 Nov 28]Google Scholar
  12. 12.
    Hamers FF, Downs AM. The changing face of the HIV epidemic in western Europe: what are the implications for public health policies? Lancet 2004; 364: 83–94PubMedCrossRefGoogle Scholar
  13. 13.
    Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antiviral Ther 2002; 7: 257–66Google Scholar
  14. 14.
    Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). Joint United Nations Programme on HIV/AIDS (UNAIDS) 2010 Available at: (http://www.unaids.org/en/KnowledgeCentre) [Accessed 2010 Nov 28]Google Scholar
  15. 15.
    Gardner LI, Klein RS, Szczech LA, et al. Rates and risk factors for condition-specific hospitalizations in HIV infected and uninfected women. J Acquir Immune Defic Syndr 2003; 34: 320–30PubMedCrossRefGoogle Scholar
  16. 16.
    Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997; 11: F101–5CrossRefGoogle Scholar
  17. 17.
    Paul S, Gilbert HM, Ziecheck W, et al. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13: 415–18PubMedCrossRefGoogle Scholar
  18. 18.
    Mocroft A, Monforte A, Kirk O, et al. Changes in hospital admissions across Europe: 19952003. Results from the Euro SIDA study. HIV Med 2004; 5: 437–47PubMedCrossRefGoogle Scholar
  19. 19.
    Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis 2006; 6: 171–7PubMedCrossRefGoogle Scholar
  20. 20.
    Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817–23PubMedCrossRefGoogle Scholar
  21. 21.
    Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963–9PubMedCrossRefGoogle Scholar
  22. 22.
    Beck EJ, Tolley K. Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy. Int J STD AIDS 1998; 9: 512–17PubMedCrossRefGoogle Scholar
  23. 23.
    Moeremans K, Annemans L, Löthgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy and Sweden. PharmacoEconomics 2010; 28 Suppl. 1: 107–28PubMedCrossRefGoogle Scholar
  24. 24.
    Caekelbergh K, Moeremans K, Annemans L, et al. Cost of care for HIV/AIDS in Belgium according to disease stage [Abstract P19.5/01]. 11th European AIDS Conference. 2007Google Scholar
  25. 25.
    Ghatnekar O, Gisslen M, Hjortsberg C, et al. Medical resource use and cost of HIV-related care in the HAART era at a university clinic in Sweden [abstract P19.10/01]. 11th European AIDS Conference. 2007Google Scholar
  26. 26.
    Organization for Economic Growth and Development. Health Data 2006. Organization for Economic Growth and Development (OECD) 2006 Accessed: 2006 Nov; Available at: (http://www.oecd.com)Google Scholar
  27. 27.
    Schmid CH, Stark PC, Berlin JA, et al. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004; 57: 683–97PubMedCrossRefGoogle Scholar
  28. 28.
    Hoffmann JP. Generalized linearmodels: an applied approach. Upper Saddle River, NJ, USA; Pearson Education, 2004Google Scholar
  29. 29.
    Roberts RR, Kampe LM, Hammerman M, et al. The cost of care for patients with HIV from the provider economic perspective. AIDS Patient Care and STDs 2006; 20: 876–86PubMedCrossRefGoogle Scholar
  30. 30.
    Garattini L, Tediosi F, Di Cintio E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS CarePsycholog Socio-Med Aspects AIDS/HIV 2001; 13: 733–41Google Scholar
  31. 31.
    Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006; 42: 1003–10PubMedCrossRefGoogle Scholar
  32. 32.
    Crane L, Crowe R, Fine S, et al. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr 2002; 30: 21–6CrossRefGoogle Scholar
  33. 33.
    Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV health care in the HAART era [abstract 537]. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO. 2006Google Scholar
  34. 34.
    Drummond M, O’Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford Medical Publications, Oxford, UK, 1997Google Scholar
  35. 35.
    Kaiser Family Foundation. HIV/AIDS Fact Sheet: the HIV Epidemic in the United States. Menlo Park, CA: 2007 [online]. Available at: (http://www.kff.org/hivaids/upload/3030-103.pdf) [Accessed 2010 Nov 28]Google Scholar
  36. 36.
    Tolley K, Gyldmark M. The treatment and care costs of people with HIV-infection or AIDS — development of a standardized cost framework for Europe. Health Policy 1993; 24: 55–70PubMedCrossRefGoogle Scholar
  37. 37.
    Palmer S, Raftery J. Economic notes: opportunity cost. BMJ 1999; 318: 1551–2PubMedCrossRefGoogle Scholar
  38. 38.
    Beck EJ, Miners AH, Tolley K. The cost ofHIV treatment and care. A global review. PharmacoEconomics 2001; 19: 13–39PubMedCrossRefGoogle Scholar
  39. 39.
    Hanvelt RA, Ruedy NS, Hogg RS, et al. Indirect costs of HIV/AIDS mortality in Canada. AIDS 1994; 8: F7–11CrossRefGoogle Scholar
  40. 40.
    Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy — Evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr 2006; 43: 451–7PubMedCrossRefGoogle Scholar
  41. 41.
    Mullins CD, Whitelaw G, Cooke SL, et al. Indirect cost of HIV infection in England. Clin Therapeut 2000; 22: 1333–45CrossRefGoogle Scholar
  42. 42.
    Rice DP, Cooper BS. The economic value of human life. Am J Public Health Nations Health 1967; 57: 1954–66PubMedCrossRefGoogle Scholar
  43. 43.
    Phillips AN, Lepri AC, Lampe F, et al. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003; 17: 1863–9PubMedCrossRefGoogle Scholar
  44. 44.
    Richman DD. Human immunodeficiency virus. International Medical Press, London, UK, 2003Google Scholar
  45. 45.
    Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824–31PubMedCrossRefGoogle Scholar
  46. 46.
    Hornberger J, Kilby JM, Wintfeld N, et al. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. AIDS Res Hum Retroviruses 2006; 22: 240–7PubMedCrossRefGoogle Scholar
  47. 47.
    Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5: 294–304PubMedCrossRefGoogle Scholar
  48. 48.
    Simpson KN, Luo MP, Chumney EC, et al. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Invest 2007; 27: 67–74CrossRefGoogle Scholar
  49. 49.
    Burman WJ, Reves RR, Cohn DL. The case for conservative management of early HIV disease. JAMA 1998; 280: 93–5PubMedCrossRefGoogle Scholar
  50. 50.
    Holmberg SD, Palella Jr FJ, Lichtenstein KA, et al. The case for earlier treatment of HIV infection. Clin Infect Dis 2004; 39: 1699–704PubMedCrossRefGoogle Scholar
  51. 51.
    Walker BD, Basgoz N. Treat HIV-1 infection like other infections — treat it. JAMA 1998; 280: 91–3PubMedCrossRefGoogle Scholar
  52. 52.
    Joint United Nations Programme on HIV/AIDS (UNAIDS). 2010 Available at: (http://www.unaids.org/en/PolicyAndPractice/ResourcesAndFunding/default.asp) [Accessed 2010 Nov 28]

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Adrian Levy
    • 1
  • Karissa Johnston
    • 2
  • Lieven Annemans
    • 3
  • Andrea Tramarin
    • 4
  • Julio Montaner
    • 5
  1. 1.Department of Community Health and EpidemiologyDalhousie UniversityNova ScotiaCanada
  2. 2.Oxford OutcomesBritish ColumbiaCanada
  3. 3.Department of Public Health, Faculty of Medicine and Health SciencesGhent University, Ghent, Belgium, and Faculty of Medicine and Pharmacy, Brussels University BrusselsBelgium
  4. 4.Ospedale Civile di VicenzaVicenzaItaly
  5. 5.Department of Medicine, University of British Columbia and Centre for Excellence in HIV/AIDSSt Paul’s HospitalVancouverCanada

Personalised recommendations